Fifth Third Wealth Advisors’s Outlook Therapeutics OTLK Stock Holding History

Fifth Third Wealth Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.74K	Hold	10,000	–	–	﹤0.01%	1068
2026 Q2	$15.9K	Buy	+10,000	New	+$6.2K	﹤0.01%	990
2025 Q3	–	Sell	-10,000	Closed	-$16K	–	804
2025 Q2	$16K	Hold	10,000	–	–	﹤0.01%	749
2025 Q1	$12.2K	Hold	10,000	–	–	﹤0.01%	704
2024 Q4	$18.9K	Buy	+10,000	New	+$41.1K	﹤0.01%	720

Other funds holding OTLK

Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

Royal Fund Management Lady Lake, Florida $1.26B AUM 23.83% 1-Year Est. Return

Christensen King & Associates Investment Services Richland, Washington $276M AUM 13.14% 1-Year Est. Return

Flower City Capital Pittsford, New York $234M AUM 15.69% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Orrstown Financial Services Harrisburg, Pennsylvania $667M AUM 15.8% 1-Year Est. Return

Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return

BWM

Bullock Wealth Management Bloomington, Indiana $241M AUM 23.31% 1-Year Est. Return

GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Fifth Third Wealth Advisors's OTLK Position: Q3 2026 in Review

Fifth Third Wealth Advisors held its Outlook Therapeutics (OTLK) position steady in Q3 2026 at 10,000 shares worth $5.74K. The position accounts for ﹤0.01% of the portfolio, ranked #1068.

Fifth Third Wealth Advisors first reported a position in OTLK in Q4 2024 and has held it in 5 quarters since. The position peaked at $18.9K in Q4 2024. 13 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.

Fifth Third Wealth Advisors held 10,000 shares of Outlook Therapeutics worth $5.74K as of Q3 2026.
Fifth Third Wealth Advisors left its Outlook Therapeutics share count unchanged in Q3 2026.
Outlook Therapeutics made up ﹤0.01% of Fifth Third Wealth Advisors's portfolio in Q3 2026, its #1068 holding.
Fifth Third Wealth Advisors first reported a position in Outlook Therapeutics in Q4 2024 and has held it in 5 quarters since.
Fifth Third Wealth Advisors's Outlook Therapeutics position peaked at $18.9K in Q4 2024.
13 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q3 2026, filed 22 Oct 2026.